RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion.
Adjuvants, Immunologic
/ metabolism
Animals
Antibodies, Viral
/ metabolism
Antibody Affinity
B-Lymphocytes
/ immunology
Cell Differentiation
Cells, Cultured
Humans
Immunologic Memory
Mice
Mice, Inbred C57BL
Plasma Cells
/ immunology
RNA
/ genetics
Signal Transduction
Toll-Like Receptor 7
/ genetics
Vaccines, Virus-Like Particle
/ immunology
Virion
adaptive immunity
anti-viral immunity
memory B cells
secondary plasma cells
toll-like receptor 7
virus-like particles
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
10
2018
accepted:
19
03
2019
entrez:
27
4
2019
pubmed:
27
4
2019
medline:
22
9
2020
Statut:
epublish
Résumé
Secondary plasma cells (PCs) originate from memory B cells and produce increased levels of antibodies with higher affinity compared to PCs generated during primary responses. Here we demonstrate that virus-like particles (VLPs) only induce secondary PCs in the presence of toll-like receptor (TLR) 7 and if they are loaded with RNA. Furthermore, adoptive transfer experiments demonstrate that RNA and TLR7 signaling are required for secondary PC generation, both at the level of memory B cell as well as PC differentiation. TLR7-signaling occurred in a B cell intrinsic manner as TLR7-deficient B cells in an otherwise TLR7-competent environment failed to differentiate into secondary PCs. Therefore, RNA inside VLPs is essential for the generation of memory B cells, which are competent to differentiate to secondary PCs and for the differentiation of secondary PCs themselves. While we have not tested all other TLR or non-TLR adjuvants with our VLPs, these data have obvious implications for vaccine design, as RNA packaged into VLPs is a simple way to enhance induction of memory B cells capable of generating secondary PCs.
Identifiants
pubmed: 31024563
doi: 10.3389/fimmu.2019.00736
pmc: PMC6467167
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
TLR7 protein, human
0
Toll-Like Receptor 7
0
Vaccines, Virus-Like Particle
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
736Références
J Exp Med. 2000 Sep 18;192(6):813-21
pubmed: 10993912
FEBS Lett. 2000 Oct 6;482(3):261-4
pubmed: 11024472
Immunity. 2001 May;14(5):617-29
pubmed: 11371363
Allergy. 2001 Jun;56(6):498-505
pubmed: 11421893
Vaccine. 2002 Aug 19;20(25-26):3104-12
pubmed: 12163261
Intervirology. 2002;45(4-6):212-7
pubmed: 12566703
Immunol Today. 1992 Nov;13(11):431-3
pubmed: 1282319
Expert Rev Vaccines. 2003 Apr;2(2):219-29
pubmed: 12899573
J Immunol. 2004 Feb 1;172(3):1777-85
pubmed: 14734761
J Immunol. 2004 Oct 1;173(7):4308-16
pubmed: 15383559
Nature. 2005 Nov 17;438(7066):364-8
pubmed: 16292312
Nat Rev Immunol. 2006 Oct;6(10):741-50
pubmed: 16977339
J Immunol. 2007 Jan 1;178(1):67-76
pubmed: 17182541
Science. 2006 Dec 22;314(5807):1936-8
pubmed: 17185603
J Immunol. 2007 Feb 15;178(4):2415-20
pubmed: 17277148
J Immunol. 2007 Jun 15;178(12):7779-86
pubmed: 17548615
Eur J Immunol. 2008 Jan;38(1):114-26
pubmed: 18081037
J Exp Med. 2009 Aug 31;206(9):2013-25
pubmed: 19703988
J Immunol. 2009 Sep 15;183(6):3788-99
pubmed: 19710454
J Immunol. 2010 May 1;184(9):4615-9
pubmed: 20368279
Immunity. 2011 Mar 25;34(3):375-84
pubmed: 21353603
J Exp Med. 2012 Mar 12;209(3):597-606
pubmed: 22370719
J Immunol. 2012 Jun 1;188(11):5389-96
pubmed: 22529295
Cell. 2012 Aug 3;150(3):606-19
pubmed: 22819539
Immunol Rev. 2013 Jan;251(1):177-88
pubmed: 23278749
J Immunol. 2014 Jun 15;192(12):5499-508
pubmed: 24821969
Autoimmunity. 2015 Feb;48(1):1-12
pubmed: 25536171
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
J Immunol. 2016 May 15;196(10):4172-84
pubmed: 27053762
Sci Rep. 2016 Jul 21;6:29063
pubmed: 27439378
Hum Vaccin Immunother. 2017 Jan 2;13(1):19-33
pubmed: 27636098
Immunology. 2017 Mar;150(3):329-342
pubmed: 27861835
J Immunol. 2017 Feb 15;198(4):1595-1605
pubmed: 28077601
J Control Release. 2017 Apr 10;251:92-100
pubmed: 28257987
J Exp Med. 2017 May 1;214(5):1259-1267
pubmed: 28363897
J Immunol. 2017 Jun 1;198(11):4205-4209
pubmed: 28432147
J Exp Med. 2017 Sep 4;214(9):2777-2794
pubmed: 28698287
Curr Opin Immunol. 2017 Aug;47:17-25
pubmed: 28728074
J Immunol. 2018 Feb 1;200(3):937-948
pubmed: 29282308
Front Immunol. 2017 Dec 19;8:1833
pubmed: 29312329
Front Immunol. 2018 Jan 10;8:1938
pubmed: 29367853
Immunity. 2018 Mar 20;48(3):584-598.e5
pubmed: 29548673
J Exp Med. 2018 Apr 2;215(4):1227-1243
pubmed: 29549115
Front Immunol. 2018 Apr 09;9:641
pubmed: 29686670
Nat Immunol. 2018 Aug;19(8):871-884
pubmed: 29988090
Cell. 1987 Mar 13;48(5):757-70
pubmed: 3493076
Mol Immunol. 1987 Jul;24(7):675-97
pubmed: 3498884
Semin Immunol. 1994 Oct;6(5):279-86
pubmed: 7532458
J Virol. 1995 Mar;69(3):1895-902
pubmed: 7853531
Annu Rev Immunol. 1997;15:235-70
pubmed: 9143688
Nature. 1997 Jul 10;388(6638):133-4
pubmed: 9217150